Yuesai Bio focuses on developing next-generation cell therapy drugs based on human pluripotent stem cell technology. Its platform covers cell preparation, culture, differentiation and gene editing. The company’s R&D and product pipeline targets neurodegenerative diseases, rare diseases and tumors. Recently the company completed an A+ funding round totaling tens of millions. The round included participation from National Science & Technology Venture Capital (Guoke Chuangtou). Proceeds are earmarked to advance its innovative stem cell therapy pipeline and accelerate clinical translation. Yuesai Biotech focuses on developing next-generation cell therapy drugs based on human pluripotent stem cell technology. The company builds a technology platform for human pluripotent stem cell preparation, culture, differentiation, and gene editing. Its R&D and product development efforts are concentrated in the stem cell therapy field. Yuesai's development pipeline covers neurodegenerative diseases, rare diseases, and cancers. The company recently completed a Series A financing round exceeding ¥100 million. The financing is intended to support continued R&D and product development within its stated areas.

Total raised

$14M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2024